Expanesthetics is working toward a bright new future for inhaled general anesthetics, a class of drugs that has been stagnant for many decades. And we're the only company developing new drugs in this category.
Historically, the innovators were mostly powered by the British Oxygen Company (acquired decades ago by Linde) and were all gobbled up in the second half of the 20th century by large financially diverse conglomerates like GE Healthcare, Baxter, Abbott (now Abbvie) and Piramal Enterprises. In our view, only four companies now remain who have both the experience as major historical anesthesia innovators and the current capacity and culture to partner with Expanesthetics to bring the next generation of drugs forward: Maruishi, Central Glass, Halocarbon, and Dräger.
Logos are owned by their representative owners, are used for identification purposes only, and do not imply endorsement or relationship.
Maruishi, a privately owned company in Osaka, Japan, first brought sevoflurane to market. The same innovative family still leads the company and many of the original researchers and leaders remain there today.
Central Glass, a public company in Tokyo, Japan, is the innovator of the sevoflurane manufacturing process and remains one of world's largest makers of sevoflurane. They remain in the business of new volatile halogenated compounds today, both at lab and industrial scale, directly and through their US subsidiary, SynQuest Labs.
Halocarbon, a private US company with roots in the Manhattan Project, was an early innovator in the production of volatile halogenated compounds and remains so today along with broader expertise in anesthetic manufacturing, direct sales, and recapture.
Dräger, a family-owned public company in Germany, invented the first anesthesia machine in 1902 and continues to be one of the largest medical device and safety equipment companies in the world.